Dárkkuhitgo:
result. » results. (Viiddit ozu)
evolveddss. » resolveddss. (Viiddit ozu)
evolved. » resolved. (Viiddit ozu)
result. » results. (Viiddit ozu)
evolveddss. » resolveddss. (Viiddit ozu)
evolved. » resolved. (Viiddit ozu)
-
21
Illustration of the result of the 3D human skeleton for flexion of the upper arm in the first data set.
Almmustuhtton 2025“…<p>Illustration of the result of the 3D human skeleton for flexion of the upper arm in the first data set.…”
-
22
Illustration of the 3D human skeleton result of flexion of the upper arm in the second data set.
Almmustuhtton 2025“…<p>Illustration of the 3D human skeleton result of flexion of the upper arm in the second data set.…”
-
23
-
24
-
25
Safety blood results across baseline, placebo, testosterone arms and the OLE.
Almmustuhtton 2023Fáttát: -
26
Modulation for the non-preferred arm does not increase with greater arm preference.
Almmustuhtton 2021Fáttát: -
27
-
28
-
29
Mechanisms and pathways of male involvement to birth outcome adapted from literature [28].
Almmustuhtton 2023Fáttát: -
30
-
31
-
32
-
33
-
34
-
35
Girl washes with soap before school during a typical morning washing routine involving the feet, legs, hands, arms and face.
Almmustuhtton 2019“…<p>Girl washes with soap before school during a typical morning washing routine involving the feet, legs, hands, arms and face.</p>…”
-
36
-
37
-
38
Sensitivity analyses results for dapagliflozin arm versus acarbose arm (results per patient).
Almmustuhtton 2016“…<p>Sensitivity analyses results for dapagliflozin arm versus acarbose arm (results per patient).…”
-
39
Base case results for dapagliflozin arm versus acarbose arm.
Almmustuhtton 2016“…<p>Base case results for dapagliflozin arm versus acarbose arm.…”
-
40
Changes in outcome measures across placebo and testosterone arms and the open label extension arm.
Almmustuhtton 2023Fáttát: